Skip to main content
TipRanks
Go Ultimate75% OFF

EyePoint Pharmaceuticals (PV3B) Stock Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

PV3B Analyst Ratings

Hold
13Ratings
2Buy10Hold1Sell
Based on 13 analysts giving stock ratings to EyePoint Pharmaceuticals in the past 3 months

PV3B Stock 12 Month Forecast

€2.35▲(834.49% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for EyePoint Pharmaceuticals in the last 3 months. The average price target is EUR 2.35 with a high forecast of EUR 4.56 and a low forecast of EUR 0.46. The average price target represents a 834.49% change from the last price of EUR 0.25.
Highest Price Target€4.56Average Price Target€2.35Lowest Price Target€0.46

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:PV3B
Price TargetArticle
Stifel Nicolaus€5.47→€4.56buy1708.69%UpsideReiterated11/13/26
H.C. Wainwright―hold―Reiterated11/13/26
Guggenheim―hold―Reiterated11/13/26
RBC Capital€0.91hold261.74%UpsideReiterated11/12/26
JonesTrading―hold―Downgraded10/23/26
Citi€15.50→€3.65buy1346.95%UpsideReiterated10/20/26
Mizuho Securities€35.55→€0.46hold80.87%UpsideDowngraded10/20/26
Laidlaw―hold―Downgraded10/20/26
Jefferies€7.29→€0.91hold261.74%UpsideDowngraded10/19/26
Chardan Capital―hold―Reiterated10/19/26
J.P. Morgan―sell―Downgraded10/19/26
Cantor Fitzgerald―hold―Reiterated10/19/26
TD Cowen€18.23→€3.65hold1346.95%UpsideDowngraded09/01/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PALIPalisade Bio
RZLTRezolute
MDWDMediwound
OVIDOvid Therapeutics
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering EyePoint Pharmaceuticals

3 Months
Tessa Romero
Tessa RomeroJ.P. Morgan
Success Rate3/7 ratings generated profit
43%
Average Return
+5.87%

Copying Tessa Romero's trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of +5.87% per trade.

1 Year
Tessa Romero
Tessa RomeroJ.P. Morgan
Success Rate3/7 ratings generated profit
43%
Average Return
+0.14%

Copying Tessa Romero's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +0.14% per trade.

2 Years
Tessa Romero
Tessa RomeroJ.P. Morgan
Success Rate3/7 ratings generated profit
43%
Average Return
-5.21%

Copying Tessa Romero's trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -5.21% per trade.

PV3B Analyst Recommendation Trends

010203040Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for PV3B
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy222822176
Buy10000
Hold0561513
Sell00011
Strong Sell00000
total2333283320

In the current month, PV3B has received 6 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. PV3B average Analyst price target in the past 3 months is 2.35.

PV3B Financial Forecast

€-2€-1.5€-1€-0.5€0Q1 2026Q3 2026Q4 2026
High€-0.36
Consensus€-0.63
Low€-0.85

PV3B Earnings Forecast

Next quarter’s earnings estimate for PV3B is -EUR 0.63 with a range of -EUR 0.85 to -EUR 0.36. The previous quarter’s EPS was -EUR 0.98. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€-1€227,894.5€455,790€683,685.5€911,581Q1 2026Q3 2026Q4 2026
High€912K
Consensus€277K
Low€0.00

PV3B Sales Forecast

Next quarter’s sales forecast for PV3B is EUR 277.12K with a range of EUR 0 to EUR 911.58K. The previous quarter’s sales results were EUR 689.15K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

PV3B Stock Forecast FAQ

What is DE:PV3B’s average 12-month price target, according to analysts?
Based on analyst ratings, EyePoint Pharmaceuticals’s 12-month average price target is €2.35.
What is DE:PV3B’s upside potential, based on the analysts’ average price target?
EyePoint Pharmaceuticals has 834.49% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is EyePoint Pharmaceuticals a Buy, Sell or Hold?
EyePoint Pharmaceuticals has a consensus rating of Hold, which is based on 2 buy ratings, 10 hold ratings and 1 sell ratings.
What is EyePoint Pharmaceuticals’s share price target?
The average share price target for EyePoint Pharmaceuticals is €2.35. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €4.56, and the lowest forecast is €0.46. The average share price target represents a 834.49% increase from the current price of €0.252.
What do analysts say about EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of EyePoint Pharmaceuticals?
To buy shares of DE:PV3B, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.